How precision medicine & AI are evolving in cancer care

Dr. Prajnan Das, department chair of Gastrointestinal (GI) Radiation Oncology at MD Anderson Cancer Center, talks about how precision medicine has evolved and how AI may actually be the technology that supercharges the conversion of the knowledge about human biology to personalized treatments that work.

Editor's Pick

Top Story How Precision Medicine and AI are Evolving: An MD Anderson Perspective Dr. Prajnan Das, department chair of Gastrointestinal (GI) Radiation Oncology at MD Anderson Cancer Center, talks about how precision medicine has evolved and how AI may actually be the technology that supercharges the conversion of the knowledge about human biology to personalized treatments that work. Sponsored How Meta Preserves a Best-in-Class Engineering Culture While Buidling Medical Devices Presented by Ketryx Join us tomorrow at 11a ET and hear from Lucas Ferandez, Director, Medical Devices at Meta as he details how the company embeds quality processes into existing systems, simplifies QMS management and automates documentation workflows within existing tools to enhance consistency and speed.  Sign up to save your spot!

Featured News

Auxira Health Secures $7.8M for Virtual Cardiology Platform Auxira Health's $7.8 million round was led by Route 66 Ventures and Abundant Venture Partners and included participation from DigiTx Partners, American Heart Association Ventures, Ensemble Innovation Ventures and City Light Capital.  Hundred Health Emerges from Stealth to Turn Health Data into Daily Action Hundred Health emerged from stealth with an app that pulls together users' medical records, lab results, wearable data and lifestyle information to create personalized, evidence-based 100-day health plans. AstraZeneca, Daiichi Sankyo ADC Enhertu Moves Up to First-Line Use in Breast Cancer FDA approval for Enhertu as a first-line breast cancer treatment is important because many patients with HER2-positive cancer do not live long enough to receive a second line of therapy. In Enhertu's pivotal study in this setting, the HER2-targeting ADC helped patients live more than three years without disease progression or death. Is Your Medical Group Ready for the January Cash Flow Crisis? It doesn't have to be this way. For the medical groups that lay the right foundation for patient collections, January is simply business as usual. Here are four ways to get ahead of the inevitable deductible reset. A Moment of Opportunity to Expand Healthcare Access in the US These two promising changes in national healthcare policy could transform access to care for millions of Americans.

Video   How Merck Views AI Asheesh Chhabra, VP & Chief Data Officer of Merck, shares how they are viewing AI.

Sponsored As Healthcare and Biopharma Companies Embrace AI, Insurance Underwriters See Risks and Opportunities Presented by Munich Re Specialty – North America In an interview, Munich Re Specialty Senior Vice President Jim Craig talked about the risk that accompanies innovation and the important role that insurers play. Learn More

Resources

Debunked Episode 21: The Drug Price Debate, AI in Healthcare Companies Face Consolidation But How Much? How many companies will be left standing once consolidation hits the AI in healthcare sector? Which pharma companies are working with the Trump administration to lower costs? View Now

MedCity News • PO Box 901 • New York, NY unsubscribe